404
+1-313-307-4176
sales@stratviewresearch.com
IBS C Drug Market Report
IBS-C Drug Market, By Product (Linaclotide, Lubiprostone, Stimulant Laxatives, Others), By Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region - COVID-19 Impact Analysis and Forecast to 2026.
Impact of COVID-19 on IBS C Drug Market
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The IBS-C Drug Market is estimated to grow from USD xx million in 2020 to USD xx million by 2026 at a healthy CAGR of 9.2% during the forecast period.
Wish to get a free sample? Register Here
Irritable bowel syndrome (IBS) is highly prevalent in the general population and has affected significantly in terms of substantial and socio-economic impact. There are around 10-20% of the population experiencing symptoms of IBS, but 15% of affected individuals seek medical treatment.
Key players operating in the IBS-C drug market are-
Owing to highly prevailing modern dietary habits, such as consumption of insoluble fiber, fried foods, and excessive intake of alcohol and caffeine, there is a surge in the number of people suffering from IBS, which propels the product demand. Moreover, severe gastrointestinal infection, rising lifestyle-oriented diseases, a growing number of patients suffering from depression, and medical advancements further augment the market growth. However, stringent FDA regulations and ignorance among people as well as some serious after-effects of the drugs used to treat IBS are likely to hamper the industry growth.
Based on product, the market has been classified into linaclotide, lubiprostone, stimulant laxatives, and others. The linaclotide segment accounted for a substantial market share in 2020. Linaclotide is an oral medication for the treatment of constipation. It is the first in a new class of drugs known as guanylate cyclase-C agonists. It is widely administered for relieving symptoms of irritable bowel syndrome (IBS) with constipation and for treating chronic constipation of unknown causes.
The market in North America accounted for the largest share in 2020 and is projected to continue its dominance during the review period. This is mainly attributed to the surge in prevalence of gastrointestinal infection cases, the large presence of advanced healthcare infrastructure, rise in a number of approval for novel IBS-C Drug, as well as presence of major market participants. In addition, the surge in R&D activities in the healthcare sector and enhancement of healthcare infrastructure, and presence of major players operating in the region, which further proliferates the regional growth.
The COVID-19 outbreak negatively affected the growth of the IBS-C Drug market. The pandemic caused added challenges for patients who are having some form of gastrointestinal infection. Due to social distancing, many hospitals have restricted appointments, and they were instead offering patient video conferencing to overcome the limitations of the market growth.
Here is the list of the group of customers that the IBS-C drug market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.
The IBS-C drug market is expected to witness an impressive growth of 9.2% CAGR in the foreseeable future.
Catalent Pharmaceuticals Solutions (US), Nestle (Switzerland), Abbott Laboratories (US), Synergy Pharmaceuticals (US), Sucampo Pharmaceuticals (US), Novartis Pharma Ag (Switzerland), Astellas Pharmaceuticals (Japan), Ardelyx, Inc (US), Synthetic Biologics, Inc (US), and Teva Pharmaceutical Industries (Israel) are the key players in the IBS-C drug market.
Severe gastrointestinal infection, rising lifestyle-oriented diseases, a growing number of patients suffering from depression, and medical advancements are the factors driving the growth of IBS-C drug market.
North America accounted for the largest share in the IBS-C drug market in 2020.
The linaclotide segment accounted for a substantial share in the IBS-C drug market in 2020.
IBS-C Drug distributors, IBS-C Drug suppliers, IBS-C Drug manufacturers, Hospitals, Government bodies are the target audience in the IBS-drug market.
WE ACCEPT
